FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

DOMAIN ASSOCIATES 		2. Issuer Name and Ticker or Trading Symbol

Tibira Therapeutics, Inc. [ TBRA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

ONE PALMER SQUARE,  		3. Date of Earliest Transaction (MM/DD/YYYY)

5/4/2015
(Street)

PRINCETON, NJ 08542
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   5/4/2015     J (6)    36187   A   (6) 38094   (7) D   (1) (2) (3) (4) (5)
 

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  The securities reported as directly beneficially owned by the designated Reporting Person may be deemed to be indirectly beneficially owned by each of the Reporting Owners listed below, each of whom is a managing member of the designated Reporting Person. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by the designated Reporting Person, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
( 2)  As managing members of the sole general partner of DP VII Associates, L.P., each Reporting Owner listed below (except for Kim P. Kamdar) may also be deemed to indirectly beneficially own 47,613 shares of Common Stock held by DP VII Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VII Associates, L.P, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
( 3)  As managing members of the sole general partner of Domain Partners VI, L.P., each Reporting Owner listed below (except for Brian K. Halak and Kim P. Kamdar) may also be deemed to indirectly beneficially own 285,679 shares of Common Stock held by Domain Partners VI, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VI, L.P, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
( 4)  As managing members of the sole general partner of DP VI Associates, L.P., each Reporting Owner listed below (except for Brian K. Halak and Kim P. Kamdar) may also be deemed to indirectly beneficially own 1,657 shares of Common Stock held by DP VI Associates, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by DP VI Associates, L.P, however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
( 5)  As managing members of the sole general partner of Domain Partners VII, L.P., each Reporting Owner listed below (except for Kim P. Kamdar) may also be deemed to indirectly beneficially own3,553,322 shares of Common Stock held by Domain Partners VII, L.P. Pursuant to Instruction 4(b)(iv) of Form 4, each such individual has elected to report as indirectly beneficially owned the entire number of securities owned by Domain Partners VII, L.P., however each of them disclaims beneficial ownership of any securities, and any proceeds thereof, that exceed his or her pecuniary interest therein and/or that are not actually distributed to him or her.
( 6)  Received in exchange for 25,302 shares of Tobira Therapeutics, Inc. ("Tobira") common stock in connection with the merger of Landmark Merger Sub Inc., a wholly owned subsidiary of the Issuer (then named Regado Biosciences, Inc.) with and into Tobira, with Tobira surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Each share of Tobira common stock outstanding immediately prior to the Merger was converted into the right to receive approximately 11.4521 shares of Common Stock. After the completion of the Merger, the Issuer changed its name to "Tobira Therapeutics, Inc."
( 7)  The number of shares of Common Stock held by the designated Reporting Person prior to the Merger is adjusted to reflect the one-for-nine reverse split of the Common Stock that was effective prior to the Merger.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
DOMAIN ASSOCIATES
ONE PALMER SQUARE
PRINCETON, NJ 08542
X

BLAIR JAMES C
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542
X

DOVEY BRIAN H
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542
X

TREU JESSE I
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542
X

SCHOEMAKER KATHLEEN K
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542
X

VITULLO NICOLE
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542
X

Halak Brian K
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542
X

Kamdar Kim P.
C/O DOMAIN ASSOCIATES, LLC
ONE PALMER SQUARE
PRINCETON, NJ 08542
X


Signatures
/s/ Kathleen K. Schoemaker, as Managing Member of Domain Associates, LLC, individually and as attorney-in-fact for J. Blair, B. Dovey, J. Treu, N. Vitullo, B. Halak and K. Kamdar 5/4/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
REGADO BIOSCIENCES INC (NASDAQ:RGDO)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more REGADO BIOSCIENCES INC Charts.
REGADO BIOSCIENCES INC (NASDAQ:RGDO)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more REGADO BIOSCIENCES INC Charts.